<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39730470</article-id><article-id pub-id-type="pmc">PMC11681247</article-id><article-id pub-id-type="publisher-id">80465</article-id><article-id pub-id-type="doi">10.1038/s41598-024-80465-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Madewell</surname><given-names>Zachary J.</given-names></name><address><email>ock0@cdc.gov</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Graff</surname><given-names>Nathan E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>Velma K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Dania M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Joshua M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maniatis</surname><given-names>Panagiotis</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Medina</surname><given-names>Freddy A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Jorge L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Briggs-Hagen</surname><given-names>Melissa</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Laura E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rivera-Amill</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Paz-Bailey</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Major</surname><given-names>Chelsea G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, </institution></institution-wrap>San Juan, Puerto Rico </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, </institution></institution-wrap>Atlanta, Georgia </aff><aff id="Aff3"><label>3</label>Eagle Health Analytics, San Antonio, Texas USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Division of Bacterial Diseases, Centers for Disease Control and Prevention, </institution></institution-wrap>Atlanta, Georgia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0022qva30</institution-id><institution-id institution-id-type="GRID">grid.262009.f</institution-id><institution>Ponce Health Sciences University/Ponce Research Institute, </institution></institution-wrap>Ponce, Puerto Rico </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><elocation-id>30743</elocation-id><history><date date-type="received"><day>1</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Understanding the dynamics of antibody responses following vaccination and SARS-CoV-2 infection is important for informing effective vaccination strategies and other public health interventions. This study investigates SARS-CoV-2 antibody dynamics in a Puerto Rican cohort, analyzing how IgG levels vary by vaccination status and previous infection. We assess waning immunity and the distribution of hybrid immunity with the aim to inform public health strategies and vaccination programs in Puerto Rico and similar settings. We conducted a prospective, longitudinal cohort study to identify SARS-CoV-2 infections and related outcomes in Ponce, Puerto Rico, from June 2020&#x02013;August 2022. Participants provided self-collected nasal swabs every week and serum every six months for RT-PCR and IgG testing, respectively. IgG reactivity against nucleocapsid (N) antigens, which generally indicate previous infection, and spike (S1) and receptor-binding domain (RBD) antigens, which indicate history of either infection or vaccination, was assessed using the Luminex Corporation xMAP&#x000ae; SARS-CoV-2 Multi-Antigen IgG Assay. Prior infection was defined by positive RT-PCRs, categorized by the predominant circulating SARS-CoV-2 variant at the event time. Demographic information, medical history, and COVID-19 vaccination history were collected through standardized questionnaires. Of 882 participants included in our analysis, 34.0% experienced at least one SARS-CoV-2 infection, with most (78.7%) occurring during the Omicron wave (December 2021 onwards). SARS-CoV-2 antibody prevalence increased over time, reaching 98.4% by the final serum collection, 67.0% attributable to vaccination alone, 1.6% from infection alone, and 31.4% from both. Regardless of prior infection status, RBD and S1 IgG levels gradually declined following two vaccine doses. A third dose boosted these antibody levels and showed a slower decline over time. N-antibody levels peaked during the Omicron surge and waned over time. Vaccination in individuals with prior SARS-CoV-2 infection elicited the highest and most durable antibody responses. N or S1 seropositivity was associated with lower odds of a subsequent positive PCR test during the Omicron period, with N antibodies showing a stronger association. By elucidating the differential decay of RBD and S1 antibodies following vaccination and the complexities of N-antibody response following infection, this study in a Puerto Rican cohort strengthens the foundation for developing targeted interventions and public health strategies.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibody dynamics</kwd><kwd>Omicron</kwd><kwd>Caribbean</kwd><kwd>COVID-19</kwd><kwd>Vaccination</kwd><kwd>Humoral immunity</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Epidemiology</kwd><kwd>Viral infection</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000030</institution-id><institution>Centers for Disease Control and Prevention</institution></institution-wrap></funding-source><award-id>U01CK000580</award-id><principal-award-recipient><name><surname>Rivera-Amill</surname><given-names>Vanessa</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The ongoing COVID-19 pandemic has spurred extensive research into diagnostic methods for current infections. Reverse transcription polymerase chain reaction (RT-PCR) and antigen tests are vital for detecting current infections, but retrospective identification of SARS-CoV-2 infections is also important for informing public health measures such as vaccine development and for understanding transmission dynamics. Serological assays offer rapid and reliable tools for identifying prior infections by detecting antibodies following SARS-CoV-2 infection<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup> These assays commonly target immunoglobulins M (IgM) and G (IgG) antibodies in humans<sup><xref ref-type="bibr" rid="CR3">3</xref></sup></p><p id="Par3">IgG antibodies are generally detectable for longer periods after infection compared to IgM and potentially play a role in long-term immunity following SARS-CoV-2 infection or vaccination. During the human immune response to SARS-CoV-2, IgG conversion typically occurs around 14&#x000a0;days post-infection, with antibodies remaining detectable for up to at least 15&#x000a0;months<sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup> Recent studies have revealed variations in immune responses to COVID-19 vaccines, with mRNA vaccines eliciting higher antibody affinity and resulting IgG titers compared to other vaccine types<sup><xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup> Receiving three or more doses of mRNA vaccines have been shown to provide greater IgG durability than completion of just two vaccine doses<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> offering strong protection against hospitalization with vaccine effectiveness estimates of 82.5% (95% CI 77.8%&#x02013;86.2%) after the third vaccine dose and 87.3% (95% CI 75.5%&#x02013;93.4%) after the fourth dose<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> Hybrid immunity, resulting from both previous infection and vaccination, has been reported to provide better protection compared to infection or vaccination alone<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> Serological assays that detect IgG antibodies against multiple SARS-CoV-2 proteins can be valuable in differentiating between previous infection and vaccination, as well as assessing potential differences in resulting immunity duration. However, knowledge gaps remain regarding the longevity of these protective responses, particularly with the emergence of new variants.</p><p id="Par4">Key IgG targets include the nucleoprotein (N) and the spike (S1) glycoprotein&#x02019;s receptor-binding domain (RBD), both major structural viral proteins of SARS-CoV-2<sup><xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref></sup> S1 interacts with the human ACE2 receptor, facilitating viral entry, whereas RBD is a specific binding site within S1 targeted by neutralizing antibodies<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> Understanding the persistence of these antibodies post-infection is essential for evaluating immunity, especially in the context of vaccination. S1 and RBD antibodies may indicate both infection-induced and vaccine-induced immunity. Conversely, N antibodies primarily indicate infection-induced immunity due to the exclusion of N protein in current FDA-approved vaccines which focus on eliciting an immune response that targets S1. In settings with high vaccination rates, N antibody assays can be helpful in distinguishing prior SARS-CoV-2 infections from vaccination-induced responses, especially for mild or asymptomatic infections which often go undetected during their acute phase<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par5">Waning of infection-induced or vaccine-induced antibodies over time is a concern, particularly with the emergence of new SARS-CoV-2 variants<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> Different variants may elicit diverse antibody responses and be variably affected by immunity from prior infections or vaccination. For example, infection with the Omicron variant has been shown to result in a higher anti-N IgG response than other variants, particularly among vaccinated individuals<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> The Omicron variant showed greater resistance to IgG neutralization generated from early (wild-type) infection or original COVID-19 monovalent vaccines, leading to relatively high infection rates in previously infected and vaccinated individuals<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> In light of these findings, further characterization of immune response durability is necessary. This includes investigating how factors such as age, underlying health conditions, and the combined effect of vaccination and infection history influence IgG persistence and resulting immunity.</p><p id="Par6">This study uses a unique Puerto Rican cohort, providing novel insights into antibody responses within a semi-isolated Caribbean population, distinct from mainland U.S. studies where vaccination rates and variant exposures differed. This is the first longitudinal analysis of its kind in Puerto Rico, investigating SARS-CoV-2 IgG antibody responses (N, S1, RBD) during 2020&#x02013;2022. The primary outcomes include the levels and durability of IgG antibodies, stratified by vaccination status, history of infection, age, and chronic conditions. We also assess potential waning of antibodies over time, variations in antibody responses based on the presumed SARS-CoV-2 variant (based on sample collection timing), and the sequence of vaccination and infection. In addition, we estimate the prevalence and persistence of hybrid immunity and analyze associations between IgG seroreactivity and subsequent SARS-CoV-2 infections. These analyses aim to enhance our understanding of long-term immunity against SARS-CoV-2, informing public health strategies and vaccination programs in Puerto Rico and similar settings.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and population</title><p id="Par7">Communities Organized to Prevent Arboviruses (COPA) is an ongoing cohort study launched in 2018 in Ponce, Puerto Rico, to assess arbovirus burden and control interventions in a community-based population. COPA is a collaboration involving Ponce Health Sciences University/Ponce Research Institute, the Puerto Rico Vector Control Unit, and the U.S. Centers for Disease Control and Prevention (CDC). Study enrollment and data collection activities are described elsewhere<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par8">A COPA sub-study for COVID-19, COCOVID, was implemented in June 2020, enrolling COPA participants and other residents from 15 selected community areas<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup> Eligible individuals were&#x02009;&#x02265;&#x02009;1&#x000a0;year old, spent four or more nights a week in the selected residence, and had no definite plans to move in the next 12&#x000a0;months. Primary study enrollment occurred from June 2020 to February 2021, with subsequent secondary enrollment until April 2022 limited to household members of active participants. Participants answered questionnaires and provided serum for multi-IgG antibody testing at enrollment and every 6&#x000a0;months until August 2022. They also provided weekly self-collected anterior nasal swabs for SARS-CoV-2 RT-PCR testing until April 2022. Additional anterior nasal swabs for expedited RT-PCR testing were collected by study staff for participants with COVID-like symptoms or close contact with a COVID-19 case during the entire COCOVID study period and until February 2023 for all participants that remained active in the COPA cohort.</p></sec><sec id="Sec4"><title>IgG antibody testing</title><p id="Par9">The Luminex xMAP<sup>&#x000ae;</sup> SARS-CoV-2 Multi-Antigen IgG Assay<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> was used according to the manufacturer&#x02019;s instructions to assess seroreactivity in COCOVID serum specimens against three key antigen components: N, S1, and RBD<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> The multiplex assay uses Luminex MagPlex beads for each IgG antigen target, and specimens were considered positive for N, S1, or RBD when their median fluorescence intensity (MFI) was&#x02009;&#x0003e;&#x02009;700 call threshold. The MFI is considered a measure of the total degree of saturation in the Luminex test platform and was used as a surrogate marker for the level of antibody titers in our analyses.</p></sec><sec id="Sec5"><title>Infection events and status</title><p id="Par10">SARS-CoV-2 infection was defined by positive RT-PCR results from nasal swabs collected weekly throughout the study period (June 2020&#x02013;August 2022), including up to 6&#x000a0;months after the participants&#x02019; final serological test. In our analyses, participant infection status at each serum collection date was assigned based on RT-PCR test results from all previously collected swabs, either as having had one or more previous RT-PCR positive results or all negative previous RT-PCR results. Positive tests separated by&#x02009;&#x02265;&#x02009;90&#x000a0;days and accompanied by at least one negative test in between were considered separate illness episodes<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par11">Based on dominant variants circulating in Puerto Rico, infection events that occurred prior to and after serum was collected for IgG testing were categorized by collection date of first positive nasal swab: pre-Delta (June 2020&#x02013;May 2021), Delta (June&#x02013;November 2021), and Omicron (December 2021&#x02013;February 2023)<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>; pre-Delta variant circulation periods were not individually defined due to low sample size. For participants with more than one apparent infection event within a 6-month period, the variant circulation period for the most recent infection was assigned.</p></sec><sec id="Sec6"><title>Vaccination status, hybrid immunity, and other participant characteristics</title><p id="Par12">Questionnaires answered by participants at enrollment and every 6&#x000a0;months during follow-up included data collection on demographics, health conditions, and COVID-19 vaccination status, including the number of doses, date of each dose, and manufacturer (Pfizer-BioNTech&#x02019;s BNT162b2, Moderna&#x02019;s mRNA-1273). Serum specimens were categorized based on the number of COVID-19 vaccine doses the participant had received prior to the collection date: unvaccinated (no doses), 1 dose, 2 doses, and 3 doses.</p><p id="Par13">Consistent with previous research<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, for the sub-analysis of hybrid immunity, vaccine-induced immunity was defined as history of at least one COVID-19 vaccination confirmed by vaccination cards, infection-induced immunity was defined as anti-N and anti-S1 antibody detection, and hybrid immunity was defined as combined protection from&#x02009;&#x02265;&#x02009;1 dose of COVID-19 vaccination, and anti-N and anti-S1 antibody detection.</p><p id="Par14">Sera were also categorized by participant age group at the time of collection (&#x0003c;&#x02009;20&#x000a0;years, 20&#x02013;39&#x000a0;years, 40&#x02013;64&#x000a0;years,&#x02009;&#x02265;&#x02009;65&#x000a0;years), and whether they had been previously diagnosed with any chronic health condition by a medical provider. Any chronic health condition included reporting one or more previously diagnosed physical or mental health conditions, and serum specimens from participants with and without specific physical conditions, including hypertension, chronic respiratory disease, diabetes, and high triglycerides, were also compared.</p></sec><sec id="Sec7"><title>Sample population</title><p id="Par15">We analyzed blood samples (serum specimens) collected at 6-, 12-, and 18-month follow-up visits from participants in the COCOVID study (December 2020&#x02013;August 2022). Blood samples from enrollment and the 24-month visit were excluded due to incomplete data on past infections using RT-PCR tests. Weekly anterior nasal swab collections for all participants ended in April 2022, before any participant reached their 24-month visit. However, RT-PCR results from anterior nasal swabs up to the 18-month visit were used to categorize IgG responses. All RT-PCR results throughout the study period, including weekly anterior nasal swabs up to April 2022 and additional swabs collected for symptomatic testing or close contact investigation, were considered to identify infections that occurred after vaccination or a documented prior infection. Blood samples from 6-, 12-, and 18-month visits were included if participants met one of the following criteria: 1) completed at least 80% of RT-PCR tests within the preceding 6&#x000a0;months, or 2) had a positive RT-PCR test result within the preceding 6&#x000a0;months. Due to the low number of participants receiving Johnson &#x00026; Johnson&#x02019;s single-dose Ad26.COV2.S vaccine in this cohort, analyses excluded serum specimens from those who only received this vaccine. However, participants who received at least one dose of an mRNA vaccine after an initial Ad26.COV2.S dose were included.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par16">The prevalence of vaccine-induced, infection-induced, or hybrid immunity was estimated for four time periods (Dec 2020&#x02013;Apr 2021, May&#x02013;Sep 2021, Oct 2021&#x02013;Feb 2022, Mar&#x02013;Aug 2022), stratified by age group. SARS-CoV-2 IgG anti-N, anti-RBD, and anti-S1 responses were assessed by days since last COVID-19 vaccine dose and vaccination status, days since RT-PCR positivity, and sequence of RT-PCR positivity and vaccination for those completing a two-dose primary series. Medians and interquartile ranges (IQR) for the MFI were calculated for each of the three IgG responses by vaccination status, days since vaccination (&#x0003c;&#x02009;14, 14&#x02013;27, 28&#x02013;89, 90&#x02013;179,&#x02009;&#x02265;&#x02009;180), and months since RT-PCR positivity (&#x0003c;&#x02009;2, 2&#x02013;4,&#x02009;&#x02265;&#x02009;5, no previous positive RT-PCR). All MFI values were log-transformed. For participants without prior RT-PCR positivity and negative anti-N antibodies, we evaluated anti-S1 and anti-RBD seropositivity by days since their last vaccine. Anti-N seropositivity rates were examined in previously infected individuals by vaccination status. Fisher&#x02019;s exact test was used to compare N seropositivity rates across vaccination groups for overall, Pre-Omicron, and Omicron periods.</p><p id="Par17">Generalized linear mixed-effects regression, with participant ID included as a random effect, was used to evaluate unadjusted and adjusted associations between anti-N, anti-RBD, and anti-S1 IgG responses and time since RT-PCR positivity, time since last vaccine dose, and chronic conditions (see Appendix <xref rid="MOESM1" ref-type="media">S1</xref> for additional details). Logistic regression with a random intercept was used to analyze associations between IgG seroreactivity and RT-PCR confirmed infection in subsequent six months during the Omicron predominant period. All available data from participants at each follow-up visit was included in the analysis, regardless of their subsequent participation status. All analyses were done using R software, version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec><sec id="Sec9"><title>Ethics declarations</title><p id="Par18">Local ethics review and approval for the COPA project and COCOVID substudy protocols were obtained through the Ponce Medical School Foundation, Inc&#x02019;s institutional review board (study #171110-VR). CDC also reviewed COPA and COCOVID protocols and determined the activities were conducted in a manner consistent with applicable federal law and CDC policy (refer to 45 C.F.R. part 46; 21 C.F.R. part 56). The authors declare that all methods were carried out in accordance with relevant guidelines and regulations. The authors declare that informed consent was obtained from all subjects.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Study population</title><p id="Par19">Among the 1,030 participants enrolled in the COCOVID study, 789 (76.6%) had qualifying serologic test results available at 6&#x000a0;months, 774 (75.1%) at 12&#x000a0;months, and 567 (55.0%) at 18&#x000a0;months following study enrollment (Table <xref rid="MOESM1" ref-type="media">S1</xref>). In total, there were 882 unique participants with one or more serologic test results included in our analyses. Median age of these participants at baseline was 37&#x000a0;years (IQR: 18&#x02013;49), 52.7% were female, and 59.3% had any chronic health condition, of which hypertension (22.4%), respiratory illness (17.2%), and diabetes (11.6%) were most frequently reported (Table <xref rid="Tab1" ref-type="table">1</xref>). By their final serologic test, 86 (9.8%) participants were unvaccinated, 10 (1.1%) had received one dose, 316 (35.8%) had received two vaccine doses, 468 (53.1%) had received three doses, and two (0.2%) had received four doses (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Descriptive characteristics of COCOVID participants, Puerto Rico, 2020&#x02013;2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">N&#x02009;=&#x02009;882<break/>n (%)</th></tr></thead><tbody><tr><td align="left"><bold>Age in years</bold> (median [IQR])</td><td align="left">37 (18&#x02013;49)</td></tr><tr><td align="left"><bold>Age group</bold></td><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;20&#x000a0;years</td><td align="left">249 (28.2)</td></tr><tr><td align="left">20&#x02013;39&#x000a0;years</td><td align="left">237 (26.9)</td></tr><tr><td align="left">40&#x02013;64&#x000a0;years</td><td align="left">300 (34.0)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;65&#x000a0;years</td><td align="left">96 (10.9)</td></tr><tr><td align="left"><bold>Sex</bold></td><td align="left"/></tr><tr><td align="left">Female</td><td align="left">465 (52.7)</td></tr><tr><td align="left">Male</td><td align="left">417 (47.3)</td></tr><tr><td align="left"><bold>Any chronic condition</bold><sup><bold>a</bold></sup></td><td align="left"/></tr><tr><td align="left">Yes</td><td align="left">523 (59.3)</td></tr><tr><td align="left">No</td><td align="left">359 (40.7)</td></tr><tr><td align="left"><bold>Follow-up visit</bold></td><td align="left"/></tr><tr><td align="left">6&#x000a0;months</td><td align="left">789 (37.0)</td></tr><tr><td align="left">12&#x000a0;months</td><td align="left">774 (36.3)</td></tr><tr><td align="left">18&#x000a0;months</td><td align="left">567 (26.6)</td></tr><tr><td align="left"><bold>COVID-19 vaccination status recorded on final visit</bold></td><td align="left"/></tr><tr><td align="left">Unvaccinated</td><td align="left">86 (9.8)</td></tr><tr><td align="left">One dose</td><td align="left">10 (1.1)</td></tr><tr><td align="left">Two doses</td><td align="left">316 (35.8)</td></tr><tr><td align="left">Three doses</td><td align="left">468 (53.1)</td></tr><tr><td align="left">Four doses</td><td align="left">2 (0.2)</td></tr><tr><td align="left"><bold>Positive SARS-CoV-2 RT-PCR during study</bold><sup><bold>b</bold></sup></td><td align="left"/></tr><tr><td align="left">Any positive RT-PCR</td><td align="left">300 (34.0)</td></tr><tr><td align="left">Pre-Delta predominant period</td><td align="left">28 (3.2)</td></tr><tr><td align="left">Delta predominant period</td><td align="left">17 (1.9)</td></tr><tr><td align="left">Omicron predominant period</td><td align="left">263 (29.8)</td></tr><tr><td align="left">No positive RT-PCR</td><td align="left">582 (66.0)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Any chronic condition included hypertension (N&#x02009;=&#x02009;198, 22.4%), chronic respiratory illness (N&#x02009;=&#x02009;152, 17.2%), diabetes (N&#x02009;=&#x02009;102, 11.6%), thyroid conditions (N&#x02009;=&#x02009;81, 9.2%), cardiac conditions (N&#x02009;=&#x02009;80, 9.1%), gastrointestinal problems (N&#x02009;=&#x02009;75, 8.5%), high triglycerides (N&#x02009;=&#x02009;72, 8.2%), asthma (N&#x02009;=&#x02009;60, 6.8%), arthritis (N&#x02009;=&#x02009;57, 6.5%), neurological disorders (N&#x02009;=&#x02009;35, 4.0%), anxiety (N&#x02009;=&#x02009;33, 3.7%), rheumatic conditions (N&#x02009;=&#x02009;28, 3.2%), depression (N&#x02009;=&#x02009;27, 3.1%), blood disorder (N&#x02009;=&#x02009;24, 2.7%), fibromyalgia (N&#x02009;=&#x02009;24, 2.7%), kidney conditions (N&#x02009;=&#x02009;24, 2.7%), cancer (N&#x02009;=&#x02009;23, 2.6%), mental illness (N&#x02009;=&#x02009;17, 1.9%), physical disabilities (N&#x02009;=&#x02009;15, 1.7%), liver conditions (N&#x02009;=&#x02009;14, 1.6%), obesity (N&#x02009;=&#x02009;14, 1.6%), stroke (N&#x02009;=&#x02009;9, 1.0%), and other (N&#x02009;=&#x02009;155, 17.6%).</p><p><sup>b</sup>Pre-Delta predominant period: June 2020&#x02013;May 2021; Delta predominant period: June&#x02013;November 2021; Omicron predominant period: December 2021&#x02013;February 2023.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>SARS-CoV-2 infection</title><p id="Par20">Of the 882 participants with one or more serologic test results, 300 (34.0%) had at least one positive SARS-CoV-2 RT-PCR test during the study period (Table <xref rid="Tab1" ref-type="table">1</xref>), with eight (2.7%) experiencing two separate RT-PCR confirmed infections. By the 18-month serologic test, 20.7% (183/882) had at least one positive RT-PCR test, with 78.7% (n&#x02009;=&#x02009;144) occurring during the Omicron predominant period (December 2021 onwards). The remaining 119 infections occurred in the 6&#x000a0;months following the final serologic test, all of which occurred during the Omicron predominant period.</p></sec><sec id="Sec13"><title>Distribution of vaccine-induced, infection-induced, and hybrid immunity over time</title><p id="Par21">The prevalence of SARS-CoV-2 antibodies indicative of prior infection or vaccination (both anti-N and anti-S1 positive or anti-N positive only) increased substantially over the study period. In the earliest analysis period (December 2020&#x02013;April 2021), only 26.9% (95% CI 23.2%, 30.9%) of 528 participants with serological test results had detectable SARS-CoV-2 antibodies. This included individuals with vaccine-induced immunity alone (25.2%), infection-induced immunity alone (0.9%), and hybrid immunity (0.8%) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). By the final period (March&#x02013;August 2022), 98.4% (95% CI 96.6%, 99.3%) of 437 participants with eligible results had SARS-CoV-2 antibodies, with 67.0% from vaccination alone, 1.6% from infection alone, and 31.4% from both. During this final period, the prevalence of hybrid immunity was highest among participants&#x02009;&#x0003c;&#x02009;20&#x000a0;years (39.3%, 95% CI 31.1%, 48.1%) and lowest among those&#x02009;&#x02265;&#x02009;65&#x000a0;years (13.0%, 95% CI 5.4%, 27.0%).<fig id="Fig1"><label>Fig.1</label><caption><p>Distribution of vaccine-induced, infection-induced, and hybrid (immunity derived from a combination of vaccination and infection) immunity<sup>a</sup> against SARS-CoV-2 by age group, Puerto Rico, 2020&#x02013;2022. <sup>a</sup>Combined detection of anti-S1 antibodies (produced by both COVID-19&#x02013;vaccination and SARS-CoV-2 infection) and anti-N antibodies (specific to prior infection), along with vaccination history from vaccination cards. <italic>Vaccine-induced immunity</italic>: Individuals with history of&#x02009;&#x02265;&#x02009;1 COVID-19 vaccination dose from vaccination card. <italic>Infection-induced immunity</italic>: Individuals with positive anti-N antibodies and positive anti-S1 antibodies. <italic>Hybrid immunity</italic>: Individuals with self-reported history of&#x02009;&#x02265;&#x02009;1 COVID-19 vaccination dose and positive antibodies for both S1 and N antigens.</p></caption><graphic xlink:href="41598_2024_80465_Fig1_HTML" id="MO1"/></fig></p><p id="Par22">The widespread availability of COVID-19 vaccines in Puerto Rico (April&#x02013;May 2021) coincided with an increase in RBD and S1 antibody titers (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A), as observed through the proportion of higher log(MFI) levels over time. Among participants previously negative for RT-PCR and N antibodies, all who had a serum sample collected within 7&#x02013;13&#x000a0;days post-second vaccine dose seroconverted for both S1 and RBD antibodies. However, by 90&#x02013;179&#x000a0;days after the second dose, S1 detection dropped to 75.6%, while RBD remained detectable in 99.1% (Figures <xref rid="MOESM1" ref-type="media">S1</xref>, <xref rid="MOESM1" ref-type="media">S2</xref>). A third vaccine dose resulted in 100% detection of both RBD and S1 antibodies at 90&#x02013;179&#x000a0;days post-vaccination.<fig id="Fig2"><label>Fig.2</label><caption><p>(<bold>A</bold>) Weekly distribution of SARS-CoV-2 N, RBD, and S1 antibody responses during the serosurvey period, represented as proportions of log-transformed median fluorescence intensity (log[MFI]) levels (e.g.,&#x02009;&#x0003c;&#x02009;3, 3&#x02013;3.5, 3.5&#x02013;4, etc.). The x-axis labels indicate months, with the number of participants tested each month shown in parentheses. The color gradient ranges from green (lower antibody levels) to red (higher antibody levels, e.g., log(MFI)&#x02009;&#x02265;&#x02009;9.5), reflecting the intensity of the immune response over time. (<bold>B</bold>) Weekly COVID-19 case counts (confirmed and probable) reported to the Puerto Rico Department of Public Health for the Ponce Health Region, 2020&#x02013;2022. These data are not part of the study cohort but are included to provide contextual information on regional COVID-19 trends. Departamento de Salud PR. COVID-19 en cifras en Puerto Rico. 2024 [cited 2024 May 17]; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.salud.pr.gov/estadisticas_v2">https://www.salud.pr.gov/estadisticas_v2</ext-link>.</p></caption><graphic xlink:href="41598_2024_80465_Fig2_HTML" id="MO2"/></fig></p><p id="Par23">N antibody levels increased dramatically during a surge of COVID-19 cases in Puerto Rico following the introduction of the Omicron variant at the end of 2021 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). This pattern aligns with Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, which shows a concurrent increase in regional COVID-19 cases during the same period. Among participants tested during this period, 28.3% (196/692) showed N IgG seroconversion, of whom 75.5% (148/196) had a previous positive RT-PCR test. Among participants who seroconverted for N antibodies, median log(MFI) for N antibodies was higher in participants with a previous positive RT-PCR (8.20, IQR 7.52, 8.70) than those with negative RT-PCRs (7.60, IQR 7.24, 8.61) regardless of vaccination status (<italic>p</italic>&#x02009;=&#x02009;0.022) (data not tabulated).</p></sec><sec id="Sec14"><title>IgG responses and waning by vaccination status</title><p id="Par24">Analysis of all serum samples suggests that RBD and S1 antibody responses were more commonly detected and persisted longer than N antibody responses across all vaccination groups (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, S3). For individuals who received two doses, the overall median log(MFI) at any time post-vaccination was 9.42 (IQR 8.93, 9.70) for RBD, 7.55 (IQR 6.86, 8.17) for S1, and 4.05 (IQR 3.37, 4.87) for N (Figure <xref rid="MOESM1" ref-type="media">S3</xref>). RBD and S1 antibodies were highly correlated regardless of vaccine dosage (<italic>r</italic>&#x02009;&#x02265;&#x02009;0.83) (Figure <xref rid="MOESM1" ref-type="media">S4</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>SARS-CoV-2 IgG antibody responses by days since last vaccine stratified by RT-PCR positivity in previous six months vs. no previous RT-PCR positivity and N negative (<bold>A</bold>) and antibody responses by days since last positive RT-PCR and vaccination status (<bold>B</bold>), Puerto Rico, 2020&#x02013;2022. The lines are loess smoothing lines and shaded bands are 95% CIs.</p></caption><graphic xlink:href="41598_2024_80465_Fig3_HTML" id="MO3"/></fig></p><p id="Par25">In participants who received two vaccine doses without a prior positive RT-PCR, both RBD and S1 levels gradually waned over time (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, S3). The median log(MFI) for RBD and S1 decreased from 9.73 (IQR 9.64, 9.83) and 8.09 (IQR 7.73, 8.38) at 14&#x02013;27&#x000a0;days post-vaccination to 8.65 (IQR 8.24, 9.12) and 6.64 (IQR 6.16, 7.26) at&#x02009;&#x02265;&#x02009;180&#x000a0;days, respectively. Younger participants (&#x0003c;&#x02009;20&#x000a0;years) had higher antibody levels than those aged&#x02009;&#x02265;&#x02009;65 at later time points (&#x0003e;&#x02009;180&#x000a0;days post-vaccination), with a median log(MFI) for S1 of 7.51 versus 6.35 (<italic>p</italic>&#x02009;=&#x02009;0.020), and for RBD, 9.22 versus 8.48 (<italic>p</italic>&#x02009;=&#x02009;0.004) (Figure <xref rid="MOESM1" ref-type="media">S5</xref>, Table <xref rid="MOESM1" ref-type="media">S3</xref>).</p><p id="Par26">Almost all antibody tests for participants who received a third vaccine dose were conducted during the Omicron predominant period. Among all serum samples collected from participants with a third dose, both RBD and S1 antibody levels peaked at 14&#x02013;27&#x000a0;days post-vaccination (median log[MFI]: 9.90, IQR 9.85, 9.94, and 9.22, IQR 9.05, 9.47, respectively), declining thereafter to 9.74 (IQR 9.48, 9.90) and 8.79 (IQR 8.33, 9.08)&#x02009;&#x02265;&#x02009;180&#x000a0;days post-vaccination, respectively (Figure <xref rid="MOESM1" ref-type="media">S3</xref>). Adjusting for age group, sex, chronic conditions, and previous infection, log(MFI) for RBD and S1 decreased by -0.002 (95% CI: -0.004, -0.001) and -0.009 (95% CI: -0.012, -0.005), respectively, for each month post-third dose (Figure <xref rid="MOESM1" ref-type="media">S6</xref>). Statistical comparisons of antibody decay rates confirmed that RBD responses decline more slowly over time compared to both S1 (<italic>Z</italic>&#x02009;=&#x02009;-3.33, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and N antibodies (<italic>Z</italic>&#x02009;=&#x02009;4.45, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). The decline rates of S1 and N antibodies were not significantly different (<italic>Z</italic>&#x02009;=&#x02009;1.67, <italic>p</italic>&#x02009;=&#x02009;0.095). RBD and S1 responses were higher for participants who received a third dose than those who with second doses regardless of age group or time since vaccination (Figure <xref rid="MOESM1" ref-type="media">S5</xref>).</p><p id="Par27">To directly assess the rate of antibody decline, we analyzed changes in IgG levels between paired serum samples collected at different time points after the second and third vaccine doses in participants with and without prior PCR-confirmed infection. For individuals with a second dose and without a previous positive RT-PCR, RBD and S1 levels fell by 8.8% (from 9.73 to 8.78) and 20.9% (from 8.44 to 6.68), respectively, after six months (Figure <xref rid="MOESM1" ref-type="media">S7</xref>). For those with a third dose and without a previous positive RT-PCR, RBD and S1 levels fell by 2.3% (from 9.82 to 9.59) and 6.2% (from 8.97 to 8.41), respectively, after six months (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). For those with a third dose and a previous positive RT-PCR, S1 levels decreased by 4.1% (from 9.21 to 8.83), while RBD levels remained stable at 9.90 after six months. There were no participants with paired SARS-CoV-2 IgG antibody responses at two time points six months apart with a second dose and a previous positive RT-PCR. N-specific antibodies for sample pairs demonstrate N levels fell by 6.9% (from 7.84 to 7.30) for those with a positive RT-PCR.<fig id="Fig4"><label>Fig. 4</label><caption><p>Paired SARS-CoV-2 IgG antibody responses for individuals at two time points six months apart among people who had received three vaccine doses by prior RT-PCR positivity, Puerto Rico, 2020&#x02013;2022. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. NS: not significant.</p></caption><graphic xlink:href="41598_2024_80465_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec15"><title>Nucleocapsid responses and RT-PCR positivity</title><p id="Par28">Among individuals with a previous positive RT-PCR (80.8% N seropositive), N antibody levels were higher (median log[MFI]: 7.89, IQR 6.90, 8.56) compared to those without a positive RT-PCR (median log[MFI]: 4.34, IQR 3.60, 5.13) (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, S3). N antibody levels peaked within two months of a positive test (median log[MFI]: 8.27, IQR 7.09, 8.69) and gradually declined thereafter, reaching a median log(MFI) of 7.24 (IQR 6.43, 8.30) at five months after testing positive. Among individuals without a history of previous infection, N-seropositivity following an infection was 83.7% and 74.6% for those who received two and three doses, respectively, not significantly different from unvaccinated individuals (77.8%) (<italic>p</italic>&#x02009;=&#x02009;0.498) (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Anti-N seropositivity rates among participants who tested positive for SARS-CoV-2 by RT-PCR at least 14&#x000a0;days after vaccination and were previously seronegative and RT-PCR negative, Puerto Rico, 2020&#x02013;2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">All</th><th align="left"/><th align="left">Pre-Omicron</th><th align="left"/><th align="left">Omicron</th></tr></thead><tbody><tr><td align="left">Vaccination status</td><td align="left"><p>Participants</p><p>N</p></td><td align="left"><p>Anti-N seropositivity</p><p>% (95% CI)</p></td><td align="left"><p>Participants</p><p>N</p></td><td align="left"><p>Anti-N seropositivity</p><p>% (95% CI)</p></td><td align="left"><p>Participants</p><p>N</p></td><td align="left"><p>Anti-N seropositivity</p><p>% (95% CI)</p></td></tr><tr><td align="left">Unvaccinated</td><td align="left">18</td><td align="left">77.8 (51.9, 92.6)</td><td align="left">16</td><td align="left">81.2 (53.7, 95.0)</td><td align="left">2</td><td align="left">50.0 (9.5, 90.5)</td></tr><tr><td align="left">Two doses</td><td align="left">49</td><td align="left">83.7 (69.8, 92.2)</td><td align="left">13</td><td align="left">69.2 (38.9, 89.6)</td><td align="left">36</td><td align="left">88.9 (73.0, 96.4)</td></tr><tr><td align="left">Three doses</td><td align="left">67</td><td align="left">74.6 (62.3, 84.1)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">67</td><td align="left">74.6 (62.3, 84.1)</td></tr><tr><td align="left">Fisher&#x02019;s exact <italic>p</italic>-value</td><td align="left"/><td align="left">0.498</td><td align="left"/><td align="left">0.448</td><td align="left"/><td align="left">0.154</td></tr></tbody></table><table-wrap-foot><p>Fisher&#x02019;s exact test was used to compare N seropositivity rates across vaccination groups for all, Pre-Omicron, and Omicron periods.</p></table-wrap-foot></table-wrap></p><p id="Par29">Both vaccination and previous RT-PCR positivity provided a stronger boost to RBD and S1 antibody responses compared to either factor alone (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, S3). The order of vaccination and RT-PCR positivity did not significantly impact antibody responses among participants who received two doses (Figure <xref rid="MOESM1" ref-type="media">S8</xref>).</p></sec><sec id="Sec16"><title>IgG seroreactivity and subsequent RT-PCR positivity</title><p id="Par30">Our analysis revealed that individuals with detectable antibodies against either N or S1 were less likely to experience a positive RT-PCR test in the following six months during the Omicron-dominant period. Specifically, N and S1 seropositivity were associated with 90.3% (95% CI 78.8%, 95.6%) and 58.3% (95% CI 12.1%, 80.2%) lower odds, respectively, of a subsequent positive test, after adjusting for age group, sex, and chronic conditions (Table <xref rid="Tab3" ref-type="table">3</xref>). Participants with a higher N antibody level (log(MFI)&#x02009;&#x02265;&#x02009;8.55) had an even greater reduction in odds (96.3%, 95% CI 73.0%, 99.5%) compared to those who were N seronegative. These findings suggest that SARS-CoV-2 infection, as indicated by N seropositivity, provided substantial protection against reinfection during the Omicron period, while vaccination, as indicated by S1 seropositivity, also offered significant, though comparatively lower, protection.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Associations between SARS-CoV-2 seroreactivity and subsequent RT-PCR positivity within six months during the Omicron predominant period, Puerto Rico, 2020&#x02013;2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>Positive RT-PCR in 6&#x000a0;months after serology</bold><break/>N&#x02009;=&#x02009;129<sup>a</sup><break/>n (%)</th><th align="left"><bold>No positive RT-PCR in 6&#x000a0;months after serology</bold><break/>N&#x02009;=&#x02009;625<sup>a</sup><break/>n (%)</th><th align="left"><bold>Odds Ratio</bold><break/><bold>(95%CI)</bold></th><th align="left"><bold>P-value</bold></th><th align="left"><bold>Adjusted</bold><sup>b</sup><bold> Odds Ratio</bold><break/><bold>(95% CI)</bold></th><th align="left"><bold>P-value</bold></th></tr></thead><tbody><tr><td align="left"><bold>S1: seroreactivity</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.003</td><td align="left"/><td char="." align="char">0.022</td></tr><tr><td align="left">Seropositive</td><td align="left">116 (89.9)</td><td align="left">602 (96.3)</td><td align="left">0.341 (0.168, 0.692)</td><td char="." align="char"/><td align="left">0.417 (0.198, 0.879)</td><td char="." align="char"/></tr><tr><td align="left">Seronegative</td><td align="left">13 (10.1)</td><td align="left">23 (3.7)</td><td align="left"><italic>Reference</italic></td><td char="." align="char"/><td align="left"><italic>Reference</italic></td><td char="." align="char"/></tr><tr><td align="left"><bold>S1: log(MFI)</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.005</td><td align="left"/><td char="." align="char">0.089</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;8.56</td><td align="left">77 (59.7)</td><td align="left">448 (71.7)</td><td align="left">0.304 (0.148, 0.626)</td><td char="." align="char"/><td align="left">0.407 (0.190, 0.870)</td><td char="." align="char"/></tr><tr><td align="left">7.56&#x02013;8.55</td><td align="left">32 (24.8)</td><td align="left">116 (18.6)</td><td align="left">0.488 (0.223, 1.070)</td><td char="." align="char"/><td align="left">0.487 (0.214, 1.106)</td><td char="." align="char"/></tr><tr><td align="left">6.56&#x02013;7.55</td><td align="left">7 (5.4)</td><td align="left">38 (6.1)</td><td align="left">0.326 (0.114, 0.936)</td><td char="." align="char"/><td align="left">0.292 (0.098, 0.873)</td><td char="." align="char"/></tr><tr><td align="left">Seronegative</td><td align="left">13 (10.1)</td><td align="left">23 (3.7)</td><td align="left"><italic>Reference</italic></td><td char="." align="char"/><td align="left"><italic>Reference</italic></td><td char="." align="char"/></tr><tr><td align="left"><bold>N: seroreactivity</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Seropositive</td><td align="left">7 (5.4)</td><td align="left">218 (34.9)</td><td align="left">0.107 (0.049, 0.234)</td><td char="." align="char"/><td align="left">0.097 (0.044, 0.212)</td><td char="." align="char"/></tr><tr><td align="left">Seronegative</td><td align="left">122 (94.6)</td><td align="left">407 (65.1)</td><td align="left"><italic>Reference</italic></td><td char="." align="char"/><td align="left"><italic>Reference</italic></td><td char="." align="char"/></tr><tr><td align="left"><bold>N: log(MFI)</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;8.56</td><td align="left">1 (0.8)</td><td align="left">184 (29.4)</td><td align="left">0.042 (0.006, 0.307)</td><td char="." align="char"/><td align="left">0.037 (0.005, 0.270)</td><td char="." align="char"/></tr><tr><td align="left">7.56&#x02013;8.55</td><td align="left">3 (2.3)</td><td align="left">155 (24.8)</td><td align="left">0.133 (0.041, 0.431)</td><td char="." align="char"/><td align="left">0.124 (0.038, 0.403)</td><td char="." align="char"/></tr><tr><td align="left">6.56&#x02013;7.55</td><td align="left">3 (2.3)</td><td align="left">148 (23.7)</td><td align="left">0.156 (0.048, 0.507)</td><td char="." align="char"/><td align="left">0.140 (0.043, 0.458)</td><td char="." align="char"/></tr><tr><td align="left">Seronegative</td><td align="left">122 (94.6)</td><td align="left">138 (22.1)</td><td align="left"><italic>Reference</italic></td><td char="." align="char"/><td align="left"><italic>Reference</italic></td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p><italic>MFI</italic> median fluorescence intensity.</p><p>Almost all (98%) antibody tests were seropositive for RBD, therefore RBD was excluded from this analysis.</p><p><sup>a</sup>The denominator is the number of serological tests performed.</p><p><sup>b</sup>Adjusted for age group, sex, and any chronic condition using mixed-effects logistic regression. All models included participant as a random effect. Associations with S1 were also adjusted for N seroreactivity; associations with N were adjusted for S1 seroreactivity.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec17"><title>Chronic conditions and IgG responses</title><p id="Par31">Among participants who received two doses, diabetes was associated with lower RBD (&#x003b2;: -0.022, 95% CI -0.039, -0.006) and S1 (&#x003b2;: -0.029, 95% CI -0.056, -0.002) responses compared to those without diabetes, after adjusting for age group, sex, and previous RT-PCR positivity (Figure <xref rid="MOESM1" ref-type="media">S9</xref>). Similarly, for participants who received a third dose, high triglycerides were associated with lower RBD (&#x003b2;: -0.009, 95% CI -0.016, -0.003) and S1 (&#x003b2;: -0.024, 95% CI -0.040, -0.007) responses compared to those with normal triglyceride levels. No significant associations were found between other chronic conditions and antibody responses.</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par32">This study provides novel real-world data on SARS-CoV-2 antibody dynamics in a semi-isolated Caribbean island population throughout the COVID-19 pandemic. This unique setting allows for a more controlled analysis of antibody response compared to geographically dispersed populations. The dataset offers insights into antibody dynamics within a population with distinct vaccination and infection histories compared to mainland populations. The high vaccination rates in Puerto Rico as the initial antigenic exposure to COVID-19, followed by infection with the Omicron variant, provide a unique population to study immunity and waning dynamics, in contrast to many U.S. populations who experienced earlier variants first and subsequent vaccination. We observed a substantial rise in seropositivity (from 26.9 to 98.4%) over the study period, including an increase in hybrid immunity from 0.8 to 31.4%. Studies have shown that hybrid immunity offers several advantages, including enhanced protection against severe disease and death, slower waning of immunity, reduced risk of reinfection, promotion of B cell diversity, and facilitation of T cell activation during subsequent vaccination<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> However, the impact of this increase on population immunity remains unclear due to the emergence and potential immune escape of SARS-CoV-2 variants. These findings emphasize the importance of ongoing surveillance and tailored vaccination strategies to effectively manage the COVID-19 pandemic.</p><p id="Par33">RBD and S1 antibody levels gradually declined over time following initial vaccine doses, reflecting the natural decay of vaccine-induced humoral immunity. S1 levels waned faster than RBD levels, consistent with previous research<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> This difference might be due to the inherent structural stability of the RBD region<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, potentially contributing to slower degradation and potentially longer-lasting protection against viral entry. However, limitations of the assay used warrant further investigation with assays optimized for S1 and RBD detection to definitively assess their relative decay rates. As expected, booster doses substantially increased RBD and S1 levels compared to the primary series, peaking 14&#x02013;27&#x000a0;days post-booster dose, indicating a rapid and robust immune response.</p><p id="Par34">Recent SARS-CoV-2 infections boosted N, RBD, and S1 antibody levels, peaking within two months and gradually declining after six months, suggesting natural humoral immunity decay. Although infection may provide protective benefits through antibody boosts, vaccination remains the safest strategy for building immunity against COVID-19, considering the risk of severe illness during infection.</p><p id="Par35">One-quarter of participants with N seroconversion during the Omicron-predominant period lacked a positive RT-PCR result. This could be due to asymptomatic or mild infections, transient viral RNA levels below the detection threshold, or infections that were too recent for RT-PCR detection. Alternatively, they could have had an acute infection that was not yet RT-PCR detectable. Supporting this hypothesis, a previous study reported declining RT-PCR sensitivity for detecting asymptomatic cases over time, with peak sensitivity occurring within the first few days after infection<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> Conversely, some participants with positive RT-PCRs had negative N tests, possibly reflecting early infection before significant antibody development. Alternatively, some individuals with mild or asymptomatic infections might not generate a strong immune response. As a result, their antibody production, including N antibodies, may be minimal or undetectable<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> These findings highlight the limitations of single testing methods and the importance of considering viral load and timing of testing when interpreting results. They also suggest the potential value of comprehensive testing approaches that combine multiple methods for more accurate diagnosis.</p><p id="Par36">Consistent with previous research<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, 84% of vaccinated individuals with their first SARS-CoV-2 infection were N-seropositive. In contrast to pre-Omicron studies<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, we observed no significant differences in N antibody detection between vaccinated and unvaccinated individuals with recent infection. Omicron&#x02019;s mutations in RBD may enhance breakthrough infections by evading vaccine-induced antibody neutralization<sup><xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>, potentially leading to increased reliance on and strengthening of the immune system&#x02019;s N antibody response. Additionally, Omicron has a higher replication rate in the nasopharynx, saliva, and upper respiratory tract compared to ancestral variants<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup> This may lead to increased shedding of viral particles, including the N protein, which the immune system can detect and generate antibodies against.</p><p id="Par37">Younger individuals (&#x0003c;&#x02009;20&#x000a0;years) had higher S1 and RBD levels than adults over 65&#x000a0;years beyond 5&#x000a0;months post-vaccination, consistent with other studies<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup> Differences associated with advancing age may be attributed to thymic involution and reduced B cell generation, differences in inflammatory response or cytokine production, and underlying comorbidities or immune modulatory medications<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> Among the explored comorbidities, diabetes and high triglycerides were associated with lower IgG responses. The inverse association with high triglyceride concentrations could be due to potential interference from triglycerides with the assay used. Although an interfering substances study was not performed for this study, it is a consideration for future investigations. For diabetes specifically, potential mechanisms include a reduced number of circulating helper T cells and impaired antigen presentation, as reported by Soetedjo et al.<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> Further research is needed to understand the specific immunological mechanisms by which certain comorbidities compromise vaccine-induced humoral immunity. These findings emphasize the need for tailored vaccination strategies, potentially involving adjuvants to enhance immune responses in older adults and considering earlier booster doses for vulnerable populations.</p><p id="Par38">This study included persons vaccinated with monovalent mRNA vaccines, initially designed against the wild-type SARS-CoV-2. While highly effective in preventing severe illness<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>, these vaccines faced declining effectiveness as newer variants emerged<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup> Over three-quarters of infections in our study occurred during the Omicron wave. Omicron sub-lineages from BA.1 to BA.5 and subsequent variants such as XBB.1.5 and JN.1 demonstrated increased transmissibility and immune escape due to S1 protein mutations, rendering the monovalent vaccines less protective<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> In response, bivalent mRNA boosters targeting both the original strain and Omicron subvariants (BA.1 or BA.4&#x02013;5) were developed for use in late 2022 and demonstrated increased effectiveness against severe outcomes with Omicron infection compared to monovalent vaccines in both laboratory and real-world studies<sup><xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref></sup> COVID-19 vaccine formulations were subsequently updated for 2023&#x02013;2024 to a new monovalent vaccine, designed to target the Omicron XBB.1.5 sub-lineage<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> The earlier bivalent and monovalent formulations are no longer authorized for use in the U.S.</p><p id="Par39">Despite waning antibody levels and variant emergence, vaccines remain an important way to prevent severe illness, hospitalization, mechanical ventilation, and death associated with COVID-19<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup> Additionally, effective treatments are available, further contributing to the reduction of severe outcomes. This protects individual health and reduces the economic burden on healthcare systems. Treating severe COVID-19 cases is costly, with inpatient stays averaging $11,275 as of March 2022<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> Widespread vaccination reduces these high-cost hospitalizations, offering clear economic benefits.</p><p id="Par40">This study was subject to several limitations. First, our analysis relied on specific antibody assays measuring IgG levels of N and S1 proteins. However, other relevant immune responses, such as B cell and T cell-mediated immunity, were not assessed. Second, this study focused on antibody levels, not directly assessing their functional effectiveness against variants. Changes in levels may not always translate to altered protection against clinical outcomes. Our findings showed an association between higher anti-N IgG levels and a decreased likelihood of a subsequent positive RT-PCR test. The relationship between antibody levels and disease severity can be complex and may vary depending on factors such as the specific variant, the type of antibodies measured (IgG versus neutralizing antibodies), and individual immune response. However, our findings align with studies suggesting that higher IgG levels may be associated with a lower risk of developing symptomatic COVID-19 infection<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>.</p><p id="Par41">Our study describes IgG responses following vaccination and infection among a cohort in Puerto Rico. Understanding the differential decay of RBD and S1 antibodies, the impact of comorbidities, and the nuances of N response following infection further informs targeted interventions and public health strategies. Some observed N and S1 serum reactivity might reflect undetected SARS-CoV-2 exposure, underscoring the value of serological testing in capturing broader population immunity compared to RT-PCR testing, which is only detectable for a short time and might miss asymptomatic or mild cases. Optimal testing to understand viral pathogenesis requires serial determinations of both viral antigens and antibody responses.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2024_80465_MOESM1_ESM.docx"><caption><p>Supplementary Information.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-024-80465-4.</p></sec><ack><title>Acknowledgements</title><p>COCOVID study staff and participants Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conception and design: ZJM, NEG, VKL, LEA, CGM; Acquisition of data: CGM, DMR; Analysis and interpretation of data: ZJM, NEG, VKL, DMR, JMW, LEA, GP, CGM; Drafting of the manuscript: Analysis and interpretation of data: ZJM, NEG, VKL, DMR, JMW, LEA, CGM; Revision of the manuscript: All authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>V. R.-A. acknowledges grant number U01CK000580 awarded by the Centers for Disease Control and Prevention.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and analyzed during the current study are not publicly available due to privacy and restrictions but are available from the corresponding author (ock0@cdc.gov) upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par42">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Disclaimer</title><p id="Par43">The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Guevara-Hoyer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Serological tests in the detection of SARS-CoV-2 antibodies</article-title><source>Diagnostics (Basel)</source><year>2021</year><pub-id pub-id-type="doi">10.3390/diagnostics11040678</pub-id><pub-id pub-id-type="pmid">33918840</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Guevara-Hoyer, K. et al. Serological tests in the detection of SARS-CoV-2 antibodies. <italic>Diagnostics (Basel)</italic>10.3390/diagnostics11040678 (2021).<pub-id pub-id-type="pmid">33918840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>GeurtsvanKessel</surname><given-names>CH</given-names></name><etal/></person-group><article-title>An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3436</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17317-y</pub-id><pub-id pub-id-type="pmid">32632160</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <italic>Nat. Commun.</italic><bold>11</bold>, 3436. 10.1038/s41467-020-17317-y (2020).<pub-id pub-id-type="pmid">32632160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaffari</surname><given-names>A</given-names></name><name><surname>Meurant</surname><given-names>R</given-names></name><name><surname>Ardakani</surname><given-names>A</given-names></name></person-group><article-title>COVID-19 serological tests: how well do they actually perform?</article-title><source>Diagnostics (Basel)</source><year>2020</year><pub-id pub-id-type="doi">10.3390/diagnostics10070453</pub-id><pub-id pub-id-type="pmid">32635444</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ghaffari, A., Meurant, R. &#x00026; Ardakani, A. COVID-19 serological tests: how well do they actually perform?. <italic>Diagnostics (Basel)</italic>10.3390/diagnostics10070453 (2020).<pub-id pub-id-type="pmid">32635444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Dehgani-Mobaraki</surname><given-names>P</given-names></name><etal/></person-group><article-title>Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model</article-title><source>Virology</source><year>2023</year><volume>578</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2022.12.003</pub-id><pub-id pub-id-type="pmid">36516688</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dehgani-Mobaraki, P. et al. Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model. <italic>Virology</italic><bold>578</bold>, 111&#x02013;116. 10.1016/j.virol.2022.12.003 (2023).<pub-id pub-id-type="pmid">36516688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Assaid</surname><given-names>N</given-names></name><etal/></person-group><article-title>Kinetics of SARS-CoV-2 IgM and IgG antibodies 3 months after COVID-19 Onset in moroccan patients</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2023</year><volume>108</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.22-0448</pub-id><pub-id pub-id-type="pmid">36509045</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Assaid, N. et al. Kinetics of SARS-CoV-2 IgM and IgG antibodies 3 months after COVID-19 Onset in moroccan patients. <italic>Am. J. Trop. Med. Hyg.</italic><bold>108</bold>, 145&#x02013;154. 10.4269/ajtmh.22-0448 (2023).<pub-id pub-id-type="pmid">36509045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Gilboa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection</article-title><source>JAMA Netw. Open</source><year>2022</year><volume>5</volume><fpage>e2231778</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.31778</pub-id><pub-id pub-id-type="pmid">36107426</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gilboa, M. et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. <italic>JAMA Netw. Open</italic><bold>5</bold>, e2231778. 10.1001/jamanetworkopen.2022.31778 (2022).<pub-id pub-id-type="pmid">36107426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Yousefi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Long-term persistence of Anti-SARS-COV-2 IgG antibodies</article-title><source>Curr. Microbiol.</source><year>2022</year><volume>79</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1007/s00284-022-02800-0</pub-id><pub-id pub-id-type="pmid">35150319</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Yousefi, Z. et al. Long-term persistence of Anti-SARS-COV-2 IgG antibodies. <italic>Curr. Microbiol.</italic><bold>79</bold>, 96. 10.1007/s00284-022-02800-0 (2022).<pub-id pub-id-type="pmid">35150319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>R</given-names></name><etal/></person-group><article-title>Humoral immune response after different SARS-CoV-2 vaccination regimens</article-title><source>BMC Med.</source><year>2022</year><volume>20</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-02231-x</pub-id><pub-id pub-id-type="pmid">35057798</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rose, R. et al. Humoral immune response after different SARS-CoV-2 vaccination regimens. <italic>BMC Med.</italic><bold>20</bold>, 31. 10.1186/s12916-021-02231-x (2022).<pub-id pub-id-type="pmid">35057798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Ailsworth</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273</article-title><source>Ann. Allergy Asthma Immunol.</source><year>2023</year><volume>130</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2022.10.003</pub-id><pub-id pub-id-type="pmid">36241020</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ailsworth, S. M. et al. Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273. <italic>Ann. Allergy Asthma Immunol.</italic><bold>130</bold>, 67&#x02013;73. 10.1016/j.anai.2022.10.003 (2023).<pub-id pub-id-type="pmid">36241020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Adjobimey</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm&#x02019;s COVID-19 vaccines</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>917905</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.917905</pub-id><pub-id pub-id-type="pmid">35799790</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Adjobimey, T. et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm&#x02019;s COVID-19 vaccines. <italic>Front. Immunol.</italic><bold>13</bold>, 917905. 10.3389/fimmu.2022.917905 (2022).<pub-id pub-id-type="pmid">35799790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Madewell</surname><given-names>ZJ</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Longini</surname><given-names>IM</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies</article-title><source>Front. Public Health</source><year>2023</year><volume>11</volume><fpage>1195908</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2023.1195908</pub-id><pub-id pub-id-type="pmid">37361171</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Song, S., Madewell, Z. J., Liu, M., Longini, I. M. &#x00026; Yang, Y. Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies. <italic>Front. Public Health</italic><bold>11</bold>, 1195908. 10.3389/fpubh.2023.1195908 (2023).<pub-id pub-id-type="pmid">37361171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Virk</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hybrid immunity provides protective advantage over vaccination or prior remote coronavirus disease 2019 alone</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><pub-id pub-id-type="doi">10.1093/ofid/ofad161</pub-id><pub-id pub-id-type="pmid">38111752</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Virk, A. et al. Hybrid immunity provides protective advantage over vaccination or prior remote coronavirus disease 2019 alone. <italic>Open Forum Infect. Dis.</italic>10.1093/ofid/ofad161 (2023).<pub-id pub-id-type="pmid">38111752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>R</given-names></name><name><surname>van Zyl</surname><given-names>M</given-names></name><name><surname>Fielding</surname><given-names>BC</given-names></name></person-group><article-title>The coronavirus nucleocapsid is a multifunctional protein</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>2991</fpage><lpage>3018</lpage><pub-id pub-id-type="doi">10.3390/v6082991</pub-id><pub-id pub-id-type="pmid">25105276</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">McBride, R., van Zyl, M. &#x00026; Fielding, B. C. The coronavirus nucleocapsid is a multifunctional protein. <italic>Viruses</italic><bold>6</bold>, 2991&#x02013;3018. 10.3390/v6082991 (2014).<pub-id pub-id-type="pmid">25105276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>XF</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>SW</given-names></name></person-group><article-title>Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19</article-title><source>Acta Pharmacol. Sin.</source><year>2020</year><volume>41</volume><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0485-4</pub-id><pub-id pub-id-type="pmid">32747721</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Huang, Y., Yang, C., Xu, X. F., Xu, W. &#x00026; Liu, S. W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. <italic>Acta Pharmacol. Sin.</italic><bold>41</bold>, 1141&#x02013;1149. 10.1038/s41401-020-0485-4 (2020).<pub-id pub-id-type="pmid">32747721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W</given-names></name><etal/></person-group><article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine</article-title><source>Cell Mol. Immunol.</source><year>2020</year><volume>17</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0400-4</pub-id><pub-id pub-id-type="pmid">32203189</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. <italic>Cell Mol. Immunol.</italic><bold>17</bold>, 613&#x02013;620. 10.1038/s41423-020-0400-4 (2020).<pub-id pub-id-type="pmid">32203189</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>NY</given-names></name><name><surname>Pang</surname><given-names>AS</given-names></name><name><surname>Chow</surname><given-names>VT</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name></person-group><article-title>Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice</article-title><source>Mil. Med. Res.</source><year>2021</year><volume>8</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s40779-021-00342-3</pub-id><pub-id pub-id-type="pmid">34465396</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Pang, N. Y., Pang, A. S., Chow, V. T. &#x00026; Wang, D. Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. <italic>Mil. Med. Res.</italic><bold>8</bold>, 47. 10.1186/s40779-021-00342-3 (2021).<pub-id pub-id-type="pmid">34465396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Follmann</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial</article-title><source>Ann. Intern. Med.</source><year>2022</year><volume>175</volume><fpage>1258</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.7326/m22-1300</pub-id><pub-id pub-id-type="pmid">35785530</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Follmann, D. et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. <italic>Ann. Intern. Med.</italic><bold>175</bold>, 1258&#x02013;1265. 10.7326/m22-1300 (2022).<pub-id pub-id-type="pmid">35785530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Pooley</surname><given-names>N</given-names></name><etal/></person-group><article-title>Durability of vaccine-induced and natural immunity against COVID-19: a narrative review</article-title><source>Infect. Dis. Ther.</source><year>2023</year><volume>12</volume><fpage>367</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1007/s40121-022-00753-2</pub-id><pub-id pub-id-type="pmid">36622633</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Pooley, N. et al. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. <italic>Infect. Dis. Ther.</italic><bold>12</bold>, 367&#x02013;387. 10.1007/s40121-022-00753-2 (2023).<pub-id pub-id-type="pmid">36622633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>JP</given-names></name><name><surname>Hassler</surname><given-names>HB</given-names></name><name><surname>Sah</surname><given-names>P</given-names></name><name><surname>Galvani</surname><given-names>AP</given-names></name><name><surname>Dornburg</surname><given-names>A</given-names></name></person-group><article-title>The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2022</year><volume>119</volume><fpage>e2204336119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2204336119</pub-id><pub-id pub-id-type="pmid">35858382</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P. &#x00026; Dornburg, A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. <italic>Proc. Natl. Acad. Sci. U. S. A.</italic><bold>119</bold>, e2204336119. 10.1073/pnas.2204336119 (2022).<pub-id pub-id-type="pmid">35858382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hornsby</surname><given-names>H</given-names></name><etal/></person-group><article-title>Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>5065</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40592-4</pub-id><pub-id pub-id-type="pmid">37604803</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hornsby, H. et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. <italic>Nat. Commun.</italic><bold>14</bold>, 5065. 10.1038/s41467-023-40592-4 (2023).<pub-id pub-id-type="pmid">37604803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Canetti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>7711</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-35480-2</pub-id><pub-id pub-id-type="pmid">36513665</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Canetti, M. et al. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. <italic>Nat. Commun.</italic><bold>13</bold>, 7711. 10.1038/s41467-022-35480-2 (2022).<pub-id pub-id-type="pmid">36513665</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Risk factors for infection with chikungunya and Zika viruses in southern Puerto Rico: A community-based cross-sectional seroprevalence survey</article-title><source>PLoS Negl. Trop Dis</source><year>2022</year><volume>16</volume><fpage>e0010416</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0010416</pub-id><pub-id pub-id-type="pmid">35696355</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Adams, L. E. et al. Risk factors for infection with chikungunya and Zika viruses in southern Puerto Rico: A community-based cross-sectional seroprevalence survey. <italic>PLoS Negl. Trop Dis</italic><bold>16</bold>, e0010416. 10.1371/journal.pntd.0010416 (2022).<pub-id pub-id-type="pmid">35696355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>DM</given-names></name><etal/></person-group><article-title>HTrack: A new tool to facilitate public health field visits and electronic data capture</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><fpage>e0244028</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0244028</pub-id><pub-id pub-id-type="pmid">33320896</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Rodr&#x000ed;guez, D. M. et al. HTrack: A new tool to facilitate public health field visits and electronic data capture. <italic>PLoS One</italic><bold>15</bold>, e0244028. 10.1371/journal.pone.0244028 (2020).<pub-id pub-id-type="pmid">33320896</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Major</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Investigating SARS-CoV-2 incidence and morbidity in ponce, Puerto Rico: protocol and baseline results from a community cohort study</article-title><source>JMIR Res. Protoc.</source><year>2024</year><volume>13</volume><fpage>e53837</fpage><pub-id pub-id-type="doi">10.2196/53837</pub-id><pub-id pub-id-type="pmid">38640475</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Major, C. G. et al. Investigating SARS-CoV-2 incidence and morbidity in ponce, Puerto Rico: protocol and baseline results from a community cohort study. <italic>JMIR Res. Protoc.</italic><bold>13</bold>, e53837. 10.2196/53837 (2024).<pub-id pub-id-type="pmid">38640475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Madewell</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Diagnostic accuracy of the abbott BINAXNOW COVID-19 antigen card test</article-title><source>Puerto Rico. Influenza Other Respir. Viruses</source><year>2024</year><volume>18</volume><fpage>e13305</fpage><pub-id pub-id-type="doi">10.1111/irv.13305</pub-id><pub-id pub-id-type="pmid">39053895</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Madewell, Z. J. et al. Diagnostic accuracy of the abbott BINAXNOW COVID-19 antigen card test. <italic>Puerto Rico. Influenza Other Respir. Viruses</italic><bold>18</bold>, e13305. 10.1111/irv.13305 (2024).<pub-id pub-id-type="pmid">39053895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Luminex. <italic>xMAP&#x000ae; SARS-CoV-2 Antibody Testing</italic>, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://www.luminexcorp.com/xmap-sars-cov-2-antibody-testing/">https://www.luminexcorp.com/xmap-sars-cov-2-antibody-testing/</ext-link>&#x0003e; (2023).</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Luminex. <italic>xMAP&#x000ae; SARS-CoV-2 Multi-Antigen IgG Assay Package Insert</italic>, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/140256/download">https://www.fda.gov/media/140256/download</ext-link>&#x0003e; (2022).</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. <italic>Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR)</italic>, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://stacks.cdc.gov/view/cdc/96072">https://stacks.cdc.gov/view/cdc/96072</ext-link>&#x0003e; (2020).</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>GA</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Omicron replacement of delta as predominant variant</article-title><source>Puerto Rico. Emerging Infectious Dis.</source><year>2023</year><volume>29</volume><fpage>855</fpage><pub-id pub-id-type="doi">10.3201/eid2904.221700</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Santiago, G. A. et al. SARS-CoV-2 Omicron replacement of delta as predominant variant. <italic>Puerto Rico. Emerging Infectious Dis.</italic><bold>29</bold>, 855 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Genomic surveillance of SARS-CoV-2 in Puerto Rico enabled early detection and tracking of variants</article-title><source>Commun. Med. (Lond)</source><year>2022</year><volume>2</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1038/s43856-022-00168-7</pub-id><pub-id pub-id-type="pmid">35968047</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Santiago, G. A. et al. Genomic surveillance of SARS-CoV-2 in Puerto Rico enabled early detection and tracking of variants. <italic>Commun. Med. (Lond)</italic><bold>2</bold>, 100. 10.1038/s43856-022-00168-7 (2022).<pub-id pub-id-type="pmid">35968047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Estimates of SARS-CoV-2 Seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status - United States, april 2021-september 2022</article-title><source>MMWR Morb. Mortal Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7222a3</pub-id><pub-id pub-id-type="pmid">37262007</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Jones, J. M. et al. Estimates of SARS-CoV-2 Seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status - United States, april 2021-september 2022. <italic>MMWR Morb. Mortal Wkly. Rep.</italic><bold>72</bold>, 601&#x02013;605. 10.15585/mmwr.mm7222a3 (2023).<pub-id pub-id-type="pmid">37262007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Lapuente</surname><given-names>D</given-names></name><name><surname>Winkler</surname><given-names>TH</given-names></name><name><surname>Tenbusch</surname><given-names>M</given-names></name></person-group><article-title>B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>144</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01095-w</pub-id><pub-id pub-id-type="pmid">37945737</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lapuente, D., Winkler, T. H. &#x00026; Tenbusch, M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. <italic>Cell Mol. Immunol.</italic><bold>21</bold>, 144&#x02013;158. 10.1038/s41423-023-01095-w (2024).<pub-id pub-id-type="pmid">37945737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults</article-title><source>Commun. Med.</source><year>2021</year><volume>1</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1038/s43856-021-00012-4</pub-id><pub-id pub-id-type="pmid">35602189</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wagner, A. et al. Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults. <italic>Commun. Med.</italic><bold>1</bold>, 13. 10.1038/s43856-021-00012-4 (2021).<pub-id pub-id-type="pmid">35602189</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyay</surname><given-names>V</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>Panja</surname><given-names>S</given-names></name><name><surname>Miyauchi</surname><given-names>R</given-names></name><name><surname>Mallela</surname><given-names>KMG</given-names></name></person-group><article-title>Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants</article-title><source>J. Biol. Chem.</source><year>2021</year><volume>297</volume><fpage>101208</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101208</pub-id><pub-id pub-id-type="pmid">34543625</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R. &#x00026; Mallela, K. M. G. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants. <italic>J. Biol. Chem.</italic><bold>297</bold>, 101208. 10.1016/j.jbc.2021.101208 (2021).<pub-id pub-id-type="pmid">34543625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Hellewell</surname><given-names>J</given-names></name><etal/></person-group><article-title>Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections</article-title><source>BMC Med.</source><year>2021</year><volume>19</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-01982-x</pub-id><pub-id pub-id-type="pmid">33902581</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Hellewell, J. et al. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. <italic>BMC Med.</italic><bold>19</bold>, 106. 10.1186/s12916-021-01982-x (2021).<pub-id pub-id-type="pmid">33902581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with Pneumonic COVID-19 patients</article-title><source>J. Clin. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.3390/jcm9072268</pub-id><pub-id pub-id-type="pmid">33352837</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ko, J. H. et al. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with Pneumonic COVID-19 patients. <italic>J. Clin. Med.</italic>10.3390/jcm9072268 (2020).<pub-id pub-id-type="pmid">33352837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>den Hartog</surname><given-names>G</given-names></name><etal/></person-group><article-title>Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>18394</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-45718-8</pub-id><pub-id pub-id-type="pmid">37884642</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">den Hartog, G. et al. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein. <italic>Sci. Rep.</italic><bold>13</bold>, 18394. 10.1038/s41598-023-45718-8 (2023).<pub-id pub-id-type="pmid">37884642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies</article-title><source>Nature</source><year>2022</year><volume>602</volume><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04385-3</pub-id><pub-id pub-id-type="pmid">35016194</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <italic>Nature</italic><bold>602</bold>, 657&#x02013;663. 10.1038/s41586-021-04385-3 (2022).<pub-id pub-id-type="pmid">35016194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5</article-title><source>Nature</source><year>2022</year><volume>608</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05053-w</pub-id><pub-id pub-id-type="pmid">35790190</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. <italic>Nature</italic><bold>608</bold>, 603&#x02013;608. 10.1038/s41586-022-05053-w (2022).<pub-id pub-id-type="pmid">35790190</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Planas</surname><given-names>D</given-names></name><etal/></person-group><article-title>Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>824</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36561-6</pub-id><pub-id pub-id-type="pmid">36788246</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Planas, D. et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <italic>Nat. Commun.</italic><bold>14</bold>, 824. 10.1038/s41467-023-36561-6 (2023).<pub-id pub-id-type="pmid">36788246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Granerud</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Omicron variant generates a higher and more sustained viral load in nasopharynx and saliva than the delta variant of SARS-CoV-2</article-title><source>Viruses</source><year>2022</year><pub-id pub-id-type="doi">10.3390/v14112420</pub-id><pub-id pub-id-type="pmid">36366518</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Granerud, B. K. et al. Omicron variant generates a higher and more sustained viral load in nasopharynx and saliva than the delta variant of SARS-CoV-2. <italic>Viruses</italic>10.3390/v14112420 (2022).<pub-id pub-id-type="pmid">36366518</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>KPY</given-names></name><etal/></person-group><article-title>Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract</article-title><source>EBioMedicine</source><year>2022</year><volume>83</volume><fpage>104232</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104232</pub-id><pub-id pub-id-type="pmid">35988466</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hui, K. P. Y. et al. Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. <italic>EBioMedicine</italic><bold>83</bold>, 104232. 10.1016/j.ebiom.2022.104232 (2022).<pub-id pub-id-type="pmid">35988466</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Karachaliou</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia</article-title><source>BMC Med.</source><year>2022</year><volume>20</volume><fpage>347</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02547-2</pub-id><pub-id pub-id-type="pmid">36109713</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Karachaliou, M. et al. SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. <italic>BMC Med.</italic><bold>20</bold>, 347. 10.1186/s12916-022-02547-2 (2022).<pub-id pub-id-type="pmid">36109713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>NE</given-names></name><etal/></person-group><article-title>Comparison of SARS-CoV-2 antibody response by age Among recipients of the BNT162b2 vs the mRNA-1273 vaccine</article-title><source>JAMA Netw. Open</source><year>2021</year><volume>4</volume><fpage>e2124331</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.24331</pub-id><pub-id pub-id-type="pmid">34473262</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Richards, N. E. et al. Comparison of SARS-CoV-2 antibody response by age Among recipients of the BNT162b2 vs the mRNA-1273 vaccine. <italic>JAMA Netw. Open</italic><bold>4</bold>, e2124331. 10.1001/jamanetworkopen.2021.24331 (2021).<pub-id pub-id-type="pmid">34473262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Bartleson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>SARS-CoV-2, COVID-19 and the aging immune system</article-title><source>Nat. Aging</source><year>2021</year><volume>1</volume><fpage>769</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00114-7</pub-id><pub-id pub-id-type="pmid">34746804</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bartleson, J. M. et al. SARS-CoV-2, COVID-19 and the aging immune system. <italic>Nat. Aging</italic><bold>1</bold>, 769&#x02013;782. 10.1038/s43587-021-00114-7 (2021).<pub-id pub-id-type="pmid">34746804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Soetedjo</surname><given-names>NNM</given-names></name><name><surname>Iryaningrum</surname><given-names>MR</given-names></name><name><surname>Lawrensia</surname><given-names>S</given-names></name><name><surname>Permana</surname><given-names>H</given-names></name></person-group><article-title>Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review</article-title><source>Diabetes Metab. Syndr.</source><year>2022</year><volume>16</volume><fpage>102406</fpage><pub-id pub-id-type="doi">10.1016/j.dsx.2022.102406</pub-id><pub-id pub-id-type="pmid">35104750</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Soetedjo, N. N. M., Iryaningrum, M. R., Lawrensia, S. &#x00026; Permana, H. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review. <italic>Diabetes Metab. Syndr.</italic><bold>16</bold>, 102406. 10.1016/j.dsx.2022.102406 (2022).<pub-id pub-id-type="pmid">35104750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ssentongo</surname><given-names>P</given-names></name><etal/></person-group><article-title>SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis</article-title><source>BMC Infect Dis.</source><year>2022</year><volume>22</volume><fpage>439</fpage><pub-id pub-id-type="doi">10.1186/s12879-022-07418-y</pub-id><pub-id pub-id-type="pmid">35525973</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ssentongo, P. et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. <italic>BMC Infect Dis.</italic><bold>22</bold>, 439. 10.1186/s12879-022-07418-y (2022).<pub-id pub-id-type="pmid">35525973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Madewell</surname><given-names>ZJ</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Longini</surname><given-names>IM</given-names><suffix>Jr</suffix></name><name><surname>Halloran</surname><given-names>ME</given-names></name><name><surname>Dean</surname><given-names>NE</given-names></name></person-group><article-title>Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis</article-title><source>JAMA Netw. Open</source><year>2022</year><volume>5</volume><fpage>e229317</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.9317</pub-id><pub-id pub-id-type="pmid">35482308</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Madewell, Z. J., Yang, Y., Longini, I. M. Jr., Halloran, M. E. &#x00026; Dean, N. E. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. <italic>JAMA Netw. Open</italic><bold>5</bold>, e229317. 10.1001/jamanetworkopen.2022.9317 (2022).<pub-id pub-id-type="pmid">35482308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Menegale</surname><given-names>F</given-names></name><etal/></person-group><article-title>Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e2310650</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.10650</pub-id><pub-id pub-id-type="pmid">37133863</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Menegale, F. et al. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. <italic>JAMA Netw. Open</italic><bold>6</bold>, e2310650. 10.1001/jamanetworkopen.2023.10650 (2023).<pub-id pub-id-type="pmid">37133863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Bhattacharya</surname><given-names>M</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Dhama</surname><given-names>K</given-names></name><name><surname>Chakraborty</surname><given-names>C</given-names></name></person-group><article-title>A detailed overview of SARS-CoV-2 Omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies</article-title><source>Viruses</source><year>2023</year><pub-id pub-id-type="doi">10.3390/v15010167</pub-id><pub-id pub-id-type="pmid">37896909</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K. &#x00026; Chakraborty, C. A detailed overview of SARS-CoV-2 Omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. <italic>Viruses</italic>10.3390/v15010167 (2023).<pub-id pub-id-type="pmid">37896909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Neutralizing activity against BQ1.1, BN.1, and XBB.1 in bivalent COVID-19 vaccine recipients: comparison by the types of prior infection and vaccine formulations</article-title><source>Vaccines (Basel)</source><year>2023</year><pub-id pub-id-type="doi">10.3390/vaccines11081320</pub-id><pub-id pub-id-type="pmid">37897024</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Hyun, H. J. et al. Neutralizing activity against BQ1.1, BN.1, and XBB.1 in bivalent COVID-19 vaccine recipients: comparison by the types of prior infection and vaccine formulations. <italic>Vaccines (Basel)</italic>10.3390/vaccines11081320 (2023).<pub-id pub-id-type="pmid">37897024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Davis-Gardner</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>183</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2214293</pub-id><pub-id pub-id-type="pmid">36546661</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. <italic>N. Engl. J. Med.</italic><bold>388</bold>, 183&#x02013;185. 10.1056/NEJMc2214293 (2023).<pub-id pub-id-type="pmid">36546661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>S</given-names></name><etal/></person-group><article-title>A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants</article-title><source>Vaccine</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.04.049</pub-id><pub-id pub-id-type="pmid">39705796</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Song, S. et al. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants. <italic>Vaccine</italic>10.1016/j.vaccine.2024.04.049 (2024).<pub-id pub-id-type="pmid">39705796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Use of updated COVID-19 vaccines 2023&#x02013;2024 formula for persons aged &#x02265;6 months: recommendations of the advisory committee on immunization practices - united states, september 2023</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7242e1</pub-id><pub-id pub-id-type="pmid">37856366</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Regan, J. J. et al. Use of updated COVID-19 vaccines 2023&#x02013;2024 formula for persons aged &#x02265;6 months: recommendations of the advisory committee on immunization practices - united states, september 2023. <italic>MMWR Morb. Mortal. Wkly. Rep.</italic><bold>72</bold>, 1140&#x02013;1146. 10.15585/mmwr.mm7242e1 (2023).<pub-id pub-id-type="pmid">37856366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Kapinos</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Inpatient costs of treating patients with COVID-19</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><fpage>e2350145</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.50145</pub-id><pub-id pub-id-type="pmid">38170519</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kapinos, K. A. et al. Inpatient costs of treating patients with COVID-19. <italic>JAMA Netw. Open</italic><bold>7</bold>, e2350145. 10.1001/jamanetworkopen.2023.50145 (2024).<pub-id pub-id-type="pmid">38170519</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Messchendorp</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Incidence and severity of COVID-19 in relation to anti-receptor-binding domain IgG antibody level after COVID-19 vaccination in kidney transplant recipients</article-title><source>Viruses</source><year>2024</year><pub-id pub-id-type="doi">10.3390/v16010114</pub-id><pub-id pub-id-type="pmid">38257814</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Messchendorp, A. L. et al. Incidence and severity of COVID-19 in relation to anti-receptor-binding domain IgG antibody level after COVID-19 vaccination in kidney transplant recipients. <italic>Viruses</italic>10.3390/v16010114 (2024).<pub-id pub-id-type="pmid">38257814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China</article-title><source>Front. Med. (Lausanne)</source><year>2023</year><volume>10</volume><fpage>1240340</fpage><pub-id pub-id-type="doi">10.3389/fmed.2023.1240340</pub-id><pub-id pub-id-type="pmid">37706028</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Chen, X. et al. Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China. <italic>Front. Med. (Lausanne)</italic><bold>10</bold>, 1240340. 10.3389/fmed.2023.1240340 (2023).<pub-id pub-id-type="pmid">37706028</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>